ReviewInternational journal of molecular sciences2025
Nanomedicine-Driven Modulation of the Gut-Brain Axis: Innovative Approaches to Managing Chronic Inflammation in Alzheimer's and Parkinson's Disease.
Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Pharmacological modulation of cGAS-STING-NLRP3 signaling by nano-immunomodulators in Alzheimer and Parkinson disease.Inflammopharmacology · 2026Review
- Neurons Die Not by One Hit, but by Signaling Convergence.Molecular neurobiology · 2026Review
- Targeting the Microbiota-Gut-Brain Axis: Emerging Nanomedicine Approaches for Neurodegenerative Diseases.The European journal of neuroscience · 2026Review
- The gut microbiota-short-chain fatty acid-inflammation axis in Parkinson's disease motor dysfunction: mechanisms and future of dietary interventions.Frontiers in neurology · 2026Review
- The gut-brain axis in pharmacology: microbiome-driven modulation of CNS drugs and neuropsychiatric outcomes.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic inflammation plays a crucial role in the pathogenesis and progression of neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), where sustained neuroinflammatory responses contribute to neuronal damage and functional decline. Recent advances in nanomedicine offer novel therapeutic strategies aimed at modulating inflammation, with a focus on targeting the gut-brain axis, a key mediator in the interplay between systemic inflammation and neurodegeneration. Artificial intelligence (AI) has emerged as a transformative tool in this context, facilitating the integration of large, complex datasets to better understand the intricate relationship between gut microbiota dysbiosis, chronic neuroinflammation, the exposome (cumulative impact of lifelong environmental exposures), and disease manifestation. AI-driven approaches and integrating exposome data with AI enable deeper insights into exposure-microbiome-inflammation interactions, enhance our understanding of the inflammatory pathways involved, support the development of predictive models for disease progression, and optimize the delivery of nanomedicine-based therapeutics. Additionally, AI applications in neuroimaging and personalized therapy planning have shown promise in addressing both motor and non-motor symptoms. This review provides a comprehensive synthesis of current knowledge, highlighting the convergence of AI, nanomedicine, and chronic inflammation in neurodegenerative disease care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.